Dr. Shen Wang is a world-famous expert in medicinal chemistry, founder of VivaVision Biotech, inventor of lifitegrast, Overseas high-level talents, leading talent of Jiaxing elite, and innovative and entrepreneurial talent of Jiangsu Province. Dr. Shen Wang graduated from the University of Pittsburgh in the United States. He has successively held important R & D positions  in well-known international enterprises such as Abbott, Sunesis and Amgen. In 2009, he served as the founder and President of Kanionusa, an overseas subsidiary of Jiangsu Kangyuan Pharmaceutical Co., Ltd., and also served as the chief scientific officer (CSO) of new drug research and development of Jiangsu Kangyuan Pharmaceutical Co., Ltd. With nearly 20 years of R & D and management experience in anti-tumor, immune system regulation, metabolic diseases, antiviral and other fields, he has led his team to develop more than 10 drugs into clinical trials, and two drugs have been approved by FDA, including lifitegrast, the only targeted treatment drug for dry eye approved by FDA in recent ten years, and venetoclax, a benchmark anticancer drug.

Mr. Ding Shizhe graduated from St. Louis University and was the co-founder of Betta capital. Prior to the founding of E-nitiate Biopharmaceuticals, he served as the director of strategic collaboration of Betta pharmaceuticals and the executive deputy general manager of Betta Dream Works  Incubator. He lead the efforts in the strategic collaboration with Meryx, Merus, Tyrogenex, Xcovery, Agenus and other domestic and foreign innovative pharmaceutical companies, Ding has rich experience in business management, strategic planning, investment, and financing.

Jun Shi, M.D., has been involved in innovative drug development for 30 years. Prior to joining E-nitiate Biopharmaceuticals, he served as Chief Development Officer of dMed (China) and was Head of Early Development and Clinical Pharmacology at Roche Innovation Center Shanghai. Prior to returning to China, he held key development and management positions at Berlex, Aventis, Forest, Daiichi-Sankyo and Allergan. He was responsible for and participated in the development and registration of several successful new drug applications in various therapeutic areas including oncology, autoimmune diseases, dermatology, anti-infection, and ophthalmology. Dr. Shi also has extensive experience in translational medicine, clinical pharmacology and quantitative pharmacology.

Jun Shi graduated from Fudan University Shanghai Medical College and completed his postdoctoral training at University of California, San Francisco in the US. He is a Visiting Professor at Peking University Clinical Research Institute, Shanghai Huashan Hospital and Anhui Medical University. Dr. Shi also holds positions such as Course Chair of CCDRS (Chinese Course of Drug Development and Regulatory Science) and Course Chair of Exploratory Clinical Development at YeeHong Business School and is a member of the ICH E11A Expert Group and CDE/NMPA Expert Group for multiple guidelines. Dr. Shi’s other memberships and positions include a fellow of American College of Clinical Pharmacology, a member of American Society of Clinical Pharmacology and Therapeutics, a member of standing committee of Chinese Society of Quantitative Pharmacology and a member of standing committee of the editorial board of Chinese Journal of Clinical Pharmacology and Therapeutics, Editor-in-Chief of Quantitative Pharmacology and New Drug Evaluation by People's Military Medical Press, and Associate Editor of Frontiers in Pharmacology.

Mr. Zhou Cheng graduated from Zhejiang University and is a Chinese certified public accountant. He has successively worked in Deloitte China and ZHEJIN trust. In 2017, he joined Betta capital as general manager and lead the investment in many high-quality innovative pharmaceutical companies such as Clover Biology (hk.2197), Righton Gene (sh.688217), Mabworks and CentryMed. Zhou also has more than ten years of financial management and investment experience.

Ms. Guo Huijie graduated from Xi'an Jiaotong University and is the Deputy Secretary General of Zhejiang life and Health Industry Innovation Committee. She has successively worked in Bank of Beijing and Sansanhui Asset Management Co., Ltd. and joined Betta capital as the investment director in 2016. Guo has lead the investment in Kintor Pharmaceutical Limited (HK.9939), VivaVision, DoubleRainbow and other high-quality innovative pharmaceutical companies, with more than ten years of experience in operation management, investment and financing.

Pengfei Liu, doctor of medicinal chemistry, served as project leader and senior project manager in Sundia pharmaceuticals and Viva Biotech. With more than 10 years of experience in drug R&D and project management, he is responsible for the early-stage R&D and overall management of the E-nitiate Bio's current product pipeline.

Ms. Jianhui Li, M.D., Ph.D., was an attending physician in the Department of Rheumatology and Immunology and a visiting scholar at Massachusetts General Hospital, Harvard Medical School. After graduating from Shanghai Jiaotong University School of Medicine with a PhD in Internal Medicine, she worked as an attending physician in the Department of Rheumatology and Immunology at Shanghai Changzheng Hospital of the Second Military Medical University for many years, where she independently supervised the ward treatment team, as well as took charge of outpatient, emergency, inpatient chief physician duties, clinical teaching and participated in several phase III clinical trials as Sub-I. Prior to joining Qiyuan Biologics, she worked for Takeda (China), GSK (China), Sanofi (China), and Shanghai Hengrui Pharmaceuticals. She was responsible for making clinical development strategies of several large and small molecules in the field of autoimmunity, developing new products pre-launch and launch medical strategies, developing studies design of phase I-IV and performing related medical affairs. She has over 10 years work experience in pharmaceutical companies. She is currently responsible for the medical affairs and clinical management of the company.

Mr. Weichao.Zheng graduated from Sun Yat-Sen University, master of pharmacyin tumor immunity, licensed pharmacist, university instructor, secretary-general of CRO industrial chain Committee of Guangdong precision Medicine Association and director of Alumni Association of School of pharmacy of Sun Yat-Sen University. He has successively worked in the pharmacy department of class Ill class A hospital, HiPower, Beiling KLLK Medical Research Co.. Ltd, ClinChoice.as the chief pharmacist, CRA, PM, clinical medical director and deputy director of project management. He has organized and conducted multiple clinical trials on small molecules and biological macromolecules, including tumorautoimmunity, skin, ophthalmology, respiration, anti infection, nephropathy and sepsis, etc. He has more than 16 years of clinical pharmacy, experience in clinical operation and project management. He is mainly responsible for the clinical operation and the whole process project management in the drug development stage of E-nitiate.

Ms. Zhang Qianqian, who graduated in Human Resources with a bachelor's degree, pursued further education at the Institute of Psychology of the Chinese Academy of Sciences. She joined Enitiatebio in June 2021. She has worked in multiple domestic and foreign innovation and entrepreneurship companies, such as Sateri Group Company under Royal Golden Eagle，RGE. With over ten years of experience in human resources management, she brings a wealth of expertise to the team.